CBG Producer Willow Biosciences Reports Record Q2 Revenue, Enters Major Pharma Deal Slated To Be Key Driver Of Growth
Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) reported on Monday its financial and operating results for the three months ended June 30, 2024, reporting significantly higher revenue and reduced costs. "The second quarter was marked by significant pipeline and revenue growth with the addition of the Laurus Labs strategic partnership that includes seven high-value APIs," Dr. Chris Savile, Willow's president and CEO, said. "In addition, the Company further strengthened its balance sheet by launching a private placement in June, which closed after the end of the quarter, and continued on its path to further increase efficiency and reduce costs."
